Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

[1]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[2]  C. Shear,et al.  Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Jean-Claude Tardif,et al.  Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.

[4]  J. Kastelein,et al.  Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis* , 2007, Current medical research and opinion.

[5]  J. Tanne.  Pfizer stops clinical trials of heart drug , 2006, BMJ : British Medical Journal.

[6]  A. Tall,et al.  The failure of torcetrapib: was it the molecule or the mechanism? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. , 2006, Journal of the American College of Cardiology.

[8]  J. Mckenney,et al.  Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. , 2006, Journal of the American College of Cardiology.

[9]  A. Tall,et al.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.

[10]  M. Milad,et al.  Model-based development of gemcabene, a new lipid-altering agent , 2005, The AAPS Journal.

[11]  M. Trip,et al.  Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. , 2005, The American journal of cardiology.

[12]  T. Sand,et al.  Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[13]  E. Stein,et al.  Pharmacotherapy for dyslipidaemia – current therapies and future agents , 2003, Expert opinion on pharmacotherapy.

[14]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Zwinderman,et al.  Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.

[16]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[17]  S. Yamashita,et al.  Pros and cons of inhibiting cholesteryl ester transfer protein , 2000, Current opinion in lipidology.

[18]  H. Suzuki,et al.  A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. , 1998, Preventive medicine.

[19]  A. Tall,et al.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. , 1996, The Journal of clinical investigation.

[20]  A. Tall.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[21]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[22]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[23]  A. Tall,et al.  Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins , 1989, Nature.

[24]  康二 梶波,et al.  Cholesteryl-Ester Transfer Activityの欠損を示す家族性高HDL血症の1家系 , 1987 .

[25]  A. Tall,et al.  Purification and characterization of a human plasma cholesteryl ester transfer protein. , 1987, The Journal of biological chemistry.

[26]  N. Miller.  Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. , 1987, American heart journal.

[27]  H. Mabuchi,et al.  Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.

[28]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[30]  D. Grobbee,et al.  Eff ect of Torcetrapib on Progression of Carotid Atherosclerosis in Heterozygous Familial Hyper- cholesterolemia , 2007 .

[31]  D. Cutler,et al.  Effect of Torcetrapib on the Progression of Coronary Atherosclerosis , 2007 .

[32]  M. Dewey,et al.  Clinical vignette. Aortocoronary collateral. , 2007, European heart journal.

[33]  J. Mckenney,et al.  P Pharmacotherapy of HDL and LDL fficacy and Safety of Torcetrapib , Novel Cholesteryl Ester Transfer Protein nhibitor , in Individuals With Below-Average igh-Density Lipoprotein Cholesterol Levels , 2006 .